FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W88975599> ?p ?o ?g. }

• W88975599 endingPage "50" @default.
• W88975599 startingPage "245" @default.
• W88975599 abstract "In nuclear medicine therapy is based on deposition of certain doses of ionizing radiation in tumors or organ tissues. Regarding their linear energy transfer (LET) values and relative biological effectiveness (RBE), principal radiotherapeuticals are alpha-, beta-, beta/gamma- or electron-emitters. In principle, to achieve the desired therapeutic effect, a particular radionuclide should exhibit adequate physical, chemical and biological properties. However, considerable efforts are required in selecting an optimal radionuclide for a specific application and then, in the development of methods for its routine production.The paper reviews several aspects of use, properties and production of unsealed radiation sources which are intended to be administered for therapeutic purposes. It covers scientific and practical criteria involved in selecting the radionuclide from medical point of view. The main indications for use of radiotherapeuticals are in oncology and rheumathology. Besides well known, like 32P, 89Sr, 90Y and 131I, several other radionuclides are also listed. Some of them are already in routine use while the others are still under investigation. The main chemical forms of radionuclides and indications are revealed. Particular emphasis is put on the discussion on criteria which a radionuclide should fulfill regarding its physical properties (type, energy, half life, ratio and abundance of the particulate and gamma ray emission). Ideally, they should, together with chemical and biological properties, match with the in-vivo pharmacokinetics and localization of the radionuclide and/or radiopharmaceutical. The trend in modern nuclear medicine is introduction of radionuclides of very specific properties. This, on the other side, opens a question of their availability on the routine basis and at reasonable prices. This matter is also discussed in the present review.Production of radionuclides for therapeutic purposes (as well as those for diagnostics) is performed either in nuclear reactors or in cyclotrons. Advantages and disadvantages of each production are discussed. The main nuclear reactions for routine production of 32P, 89Sr, 90Y and 131I are given, as well as for production of several other reactor or cyclotron-produced radionuclides. These are, e.g., reactor-produced beta-emitter 169Er, beta/gamma emitters 67Cu, 153Sm, 165Dy, 186Re and electron-emitters 80mBr and 125I. Generators for production of alpha emitters 212Bi and 213Bi are also under development. It can be concluded that, at present, besides 131I, large activities of 32P, 89Sr and 90Y are available on regular basis. For many others, routine availability remains yet to be established." @default.
• W88975599 created "2016-06-24" @default.
• W88975599 creator A5071396828 @default.
• W88975599 creator A5075623850 @default.
• W88975599 date "2002-01-05" @default.
• W88975599 modified "2023-10-14" @default.
• W88975599 title "[Use of radionuclides in therapy]." @default.
• W88975599 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11759220" @default.
• W88975599 hasPublicationYear "2002" @default.
• W88975599 type Work @default.
• W88975599 sameAs 88975599 @default.
• W88975599 citedByCount "0" @default.
• W88975599 crossrefType "journal-article" @default.
• W88975599 hasAuthorship W88975599A5071396828 @default.
• W88975599 hasAuthorship W88975599A5075623850 @default.
• W88975599 hasConcept C111337013 @default.
• W88975599 hasConcept C121332964 @default.
• W88975599 hasConcept C127413603 @default.
• W88975599 hasConcept C158973077 @default.
• W88975599 hasConcept C177322064 @default.
• W88975599 hasConcept C18231593 @default.
• W88975599 hasConcept C183696295 @default.
• W88975599 hasConcept C185544564 @default.
• W88975599 hasConcept C185592680 @default.
• W88975599 hasConcept C19527891 @default.
• W88975599 hasConcept C2989005 @default.
• W88975599 hasConcept C2993559085 @default.
• W88975599 hasConcept C71924100 @default.
• W88975599 hasConceptScore W88975599C111337013 @default.
• W88975599 hasConceptScore W88975599C121332964 @default.
• W88975599 hasConceptScore W88975599C127413603 @default.
• W88975599 hasConceptScore W88975599C158973077 @default.
• W88975599 hasConceptScore W88975599C177322064 @default.
• W88975599 hasConceptScore W88975599C18231593 @default.
• W88975599 hasConceptScore W88975599C183696295 @default.
• W88975599 hasConceptScore W88975599C185544564 @default.
• W88975599 hasConceptScore W88975599C185592680 @default.
• W88975599 hasConceptScore W88975599C19527891 @default.
• W88975599 hasConceptScore W88975599C2989005 @default.
• W88975599 hasConceptScore W88975599C2993559085 @default.
• W88975599 hasConceptScore W88975599C71924100 @default.
• W88975599 hasIssue "5-6" @default.
• W88975599 hasLocation W889755991 @default.
• W88975599 hasOpenAccess W88975599 @default.
• W88975599 hasPrimaryLocation W889755991 @default.
• W88975599 hasRelatedWork W199947214 @default.
• W88975599 hasRelatedWork W2029790311 @default.
• W88975599 hasRelatedWork W2083629115 @default.
• W88975599 hasRelatedWork W2148878903 @default.
• W88975599 hasRelatedWork W24527022 @default.
• W88975599 hasRelatedWork W2618750228 @default.
• W88975599 hasRelatedWork W2883658939 @default.
• W88975599 hasRelatedWork W2967167352 @default.
• W88975599 hasRelatedWork W4225254756 @default.
• W88975599 hasRelatedWork W62288865 @default.
• W88975599 hasVolume "54" @default.
• W88975599 isParatext "false" @default.
• W88975599 isRetracted "false" @default.
• W88975599 magId "88975599" @default.
• W88975599 workType "article" @default.